



CELLUMEN FINDS INCREASED PREDICTIVITY FOR HUMAN DILI THROUGH RAT HEPATOCYTE PANEL

Less expensive, more reliable rodent panel offers both predictivity and mechanistic profiles

Pittsburgh, PA, November 5, 2009 – [Cellumen, Inc.](#), a discovery and early safety assessment company, today announced that its *in vitro* Rat Hepatocyte Early Safety Assessment Panel provides increased predictivity for human drug induced liver injury (DILI) equivalent to that of a recently published panel comprised of human hepatocytes. The implications of this study have a significant impact on cost and throughput for *in vitro* human DILI predictive solutions.

As a result of these findings, less expensive, more reliable cells from a rat coupled with a 384-well assay format can result in reliable classification and risk-ranking of compounds for purposes of hit-to-lead prioritization and chemical class selection. In addition, the Cellumen *in vitro* rodent safety assessment panel provides robust dose- and time-dependent mechanistic profiles for each compound, allowing for de-risking compounds for specific mechanisms of toxicity.

The internal study, completed by Cellumen, focused on a set of 178 compounds spanning diverse chemical classes with published human DILI scores. Cellumen applied its proprietary Rat Hepatocyte Early Safety Assessment Panel consisting of freshly harvested hepatocytes, eight cellular features, three time points, and a 10 point dose response. The panel was analyzed on a high-content imaging platform and a classifier constructed to predict human DILI scores. Using this optimized Rodent Hepatocyte Panel, Cellumen achieved 100 percent specificity with nearly 50 percent sensitivity.

“We were excited by these findings, since we did not expect the concordance of human-to-human and rat-to-human DILI predictivity to be so strong,” says Don Taylor, Vice President of Corporate Development for Cellumen. “However, since Cellumen measured molecular mechanisms common to both species, these results may not be as surprising as initially thought.”

The results indicate that its *in vitro* Rat Hepatocyte Early Safety Assessment Panel can offer Cellumen customers higher throughput and lower cost solutions for human DILI predictivity than other options currently available.

About Cellumen

Cellumen is the leading early safety assessment innovator providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen’s Cellular Systems Biology solutions are driving early safety assessment by addressing the full complexity of disease and safety. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of [Safeguard Scientifics](#). Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit www.cellumen.com.

Cellumen Media Contact

Theresa Murray

Gregory FCA

610-642-8253 x164

Theresa@GregoryFCA.com